Renhuang Pharmaceuticals, Inc. (RHGP.OB) Rated “Outperform” and Awarded Target Price of $7
Renhuang Pharmaceuticals, Inc has recently been rated as 'Sector Outperform' by Beacon Equity Research; and thus, a target price of $7.00 has also been issued. Renhuang Pharmaceuticals is a leading company focused on manufacturing and distributing a broad line of high-quality nutraceutical, natural medicinal and bio-pharmaceutical products in mainland China. The company's three major product lines consist of: Acanthopanax-based natural medicinal products, the Shark Power healthcare series, and traditional Chinese medicines. Renhuang, since their initial formation, has been able to successfully establish a leading research and development infrastructure that consists of in-house researchers, a post-doctoral working center, and collaborations with…